Digital Trials Digest, our quarterly newsletter
A quarterly look at what's new in ObvioGo, where decentralized trials are heading, and the partnerships shaping what's next — new Image Capture & Central Rating features, caregiver-collected growth data research, and what's coming in OG-2.10.
Issue 2: new Assent & Countersignature capabilities, ObvioGo's direct integration with Oracle Health and Life Sciences, Novotech's multi-trial licensing agreement, and SCOPE 2026 takeaways.
Issue 1: ObvioGo's new built-in eSignature, the Template Library and Out-of-Window Data Submissions features, caregiver-centric eDiary design, and how MiHelper accelerated a decentralized migraine study.
Patient monitoring for high-touch therapies takes more than remote data collection. See how ObvioHealth and SPRIM PRO connect capture, clinical oversight, and support into one coordinated program.
As decentralized trials scale, central rating workflows must keep pace. Here's a clear look at what central rating is, where it fits in trial operations, and why integrated platform delivery is changing the way sponsors manage independent endpoint review.
Most decentralized platforms solve the image capture problem. They don’t solve the rating problem. Here’s what regulatory-grade central rating actually requires for AD, HS, psoriasis, and urticaria programs.
A new forecast puts the global eCOA solutions market at $7.46 billion by 2036. Here’s what that growth means for sponsors — and why the platforms that will lead it were built to run trials, not just support them.
The conversation at SCOPE 2026 wasn't about what's possible in clinical trials — it was about why it's still so hard to execute. Here's what we heard on the ground.